Akeso

Summit Therapeutics announces Phase III HARMONi-2 trial results showing ivonescimab's superior PFS (11.14 months vs. 5.82 months for pembrolizumab) in advanced NSCLC, with comparable safety profiles. The company plans to initiate HARMONi-7 in early 2025, a multi-regional Phase III trial for first-line PD-L1 high metastatic NSCLC.

Innovent Biologics' earnings report shows revenue up 46% to 3.95 billion yuan, but net loss surges 182% to 393 million yuan. The delay in sales approval for anti-obesity drug mazdutide and the sudden retirement of R&D chief Liu Yongjun dampen investor enthusiasm. Innovent's focus shifts to cardiovascular and metabolic drugs, with mazdutide and teprotumumab in the pipeline.